BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NeuroDigm Reveals How Chronic Pain Begins in a GEL Animal Model of Neuropathic Pain


6/12/2012 9:34:09 AM

June 12, 2012 -- By exploring the natural origin of nerve pain NeuroDigm Co. opens a new field in preclinical pain research. Currently biotech and pharma companies perform analgesic candidate screening using rodent models created mainly by nerve transection or ligation. Use of these nerve trauma models has resulted in few new analgesic candidates over decades.

The major cause of neuropathic pain according to Mary Hannaman MD, President of NeuroDigm Co., is inflammation created by tissue repair not nerve damage. Forms of cold, heat, chemicals, metal, ligatures, compression and nerve trauma or transection create current neuropathic pain models. These methods are not representative of the cause of the majority of persistent nerve pain cases seen by physicians.

To enable solutions NeuroDigm has developed a nonsurgical rodent model created by the injection of a gel. The GEL Neuropathic Pain Model stimulates a change in the extracellular matrix causing the gradual onset of fibrosis that creates a natural stricture. The gentle compression caused by this method produces inflammation without clinical or histological evidence of nerve damage.

Neural regeneration may be represented in The GEL Neuropathic Pain model, since the pain behaviors are gradual in onset yet robust and persist with increasing intensity over 6 months and longer. Dr. Hannaman says tissue repair and neural regeneration can refocus preclinical pain research enabling more successful analgesics, and targeted treatments with biologics.

The GEL Neuropathic Pain model represents the pain syndromes that may gradually occur after musculoskeletal strains, industrial overuse conditions, surgeries, minor trauma, nerve entrapments and back strains.

NeuroDigm Co. LLC business office is located in Colorado Springs, CO. The company focuses on research and development related to neuropathic pain solutions to aid companies in pain research. Preclinical contract research services are available. The company has U.S. Patents on The GEL Model??? 7015371, 7388124.

Contact: Mary Hannaman mary.hannaman@neurodigm.com

Superscript needed for TM in last line.



Read at BioSpace.com

NeuroDigm
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES